We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) focuses on three core businesses – Pharmaceuticals, Vaccines and Consumer Healthcare. Glaxo enjoys strong fundamentals in the form of its diversified base and presence in different geographical areas.
This UK-based company reshaped its business, following the completion of the three-part, inter-conditional transaction with Novartis (NVS - Free Report) in March 2015. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines).
Here are four reasons why you should invest in the stock this year.
Good Rank and Solid VGM Score: Glaxo carries a Zacks Rank #2 (Buy) and a favorable VGM Score of A. Back-tested results show that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best upside potential. You can see the complete list of today’s Zacks #1 Rank stocks here.
Rising Share Price and Estimates: After underperforming the broader industry in 2017, Glaxo’s shares have picked up this year. Glaxo’s stock has risen 5.4% this year so far, which compares favorably with a flat trajectory for the industry.
Meanwhile, estimates for 2018 and 2019 rose 1.4% and 1.7%, respectively in the past 30 days.
This pharma giant has been consistently beating earnings expectations. Its earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 2.12%.
New Drugs/Vaccines Doing Well: Glaxo’s newer respiratory/HIV drugs and vaccines are all doing well and will continue to boost revenues. These new products generated 22% of Glaxo’s Pharmaceuticals and Vaccine sales in 2016 and 30% in 2017 and should continue to boost revenues significantly.
Glaxo had expected the new pharmaceutical and vaccine products including contributions from Shingrix to deliver sales of £6 billion per annum by 2020. However, these products almost reached the £6 billion target in 2017.
Significant Progress with Pipeline: Glaxo has made significant progress with its late-stage pipeline. In 2017, Glaxo received approvals for three key new drugs, Shingrix vaccine for shingles, which enjoys preferential recommendation from ACIP; Trelegy Ellipta, which provides three medicines in a single inhaler to treat COPD and Juluca (dolutegravir and rilpivirine), the first 2-drug regimen, once-daily, single pill for HIV. Back-to-back approvals of three new products have strengthened Glaxo’s competitive position.
Juluca has been developed by Glaxo and partner Pfizer, Inc.’s (PFE - Free Report) HIV-focused company, ViiV Healthcare, in partnership with Johnson & Johnson (JNJ - Free Report) .
Glaxo is also working on expanding the label of marketed products like Nucala into additional indications
Conclusion
Glaxo faces its share of challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets.Meanwhile, its top-selling respiratory product, Advair is also expected to face generic competition in the United States this year, which will hurt sales.
However, it looks like Glaxo’s strong pipeline, consistent outperformance of new HIV drugs and vaccines, three new products, and cost cuts can bring it back on track this year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
GlaxoSmithKline plc (GSK - Free Report) focuses on three core businesses – Pharmaceuticals, Vaccines and Consumer Healthcare. Glaxo enjoys strong fundamentals in the form of its diversified base and presence in different geographical areas.
This UK-based company reshaped its business, following the completion of the three-part, inter-conditional transaction with Novartis (NVS - Free Report) in March 2015. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines).
Here are four reasons why you should invest in the stock this year.
Good Rank and Solid VGM Score: Glaxo carries a Zacks Rank #2 (Buy) and a favorable VGM Score of A. Back-tested results show that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best upside potential. You can see the complete list of today’s Zacks #1 Rank stocks here.
Rising Share Price and Estimates: After underperforming the broader industry in 2017, Glaxo’s shares have picked up this year. Glaxo’s stock has risen 5.4% this year so far, which compares favorably with a flat trajectory for the industry.
Meanwhile, estimates for 2018 and 2019 rose 1.4% and 1.7%, respectively in the past 30 days.
This pharma giant has been consistently beating earnings expectations. Its earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 2.12%.
New Drugs/Vaccines Doing Well: Glaxo’s newer respiratory/HIV drugs and vaccines are all doing well and will continue to boost revenues. These new products generated 22% of Glaxo’s Pharmaceuticals and Vaccine sales in 2016 and 30% in 2017 and should continue to boost revenues significantly.
Glaxo had expected the new pharmaceutical and vaccine products including contributions from Shingrix to deliver sales of £6 billion per annum by 2020. However, these products almost reached the £6 billion target in 2017.
Significant Progress with Pipeline: Glaxo has made significant progress with its late-stage pipeline. In 2017, Glaxo received approvals for three key new drugs, Shingrix vaccine for shingles, which enjoys preferential recommendation from ACIP; Trelegy Ellipta, which provides three medicines in a single inhaler to treat COPD and Juluca (dolutegravir and rilpivirine), the first 2-drug regimen, once-daily, single pill for HIV. Back-to-back approvals of three new products have strengthened Glaxo’s competitive position.
Juluca has been developed by Glaxo and partner Pfizer, Inc.’s (PFE - Free Report) HIV-focused company, ViiV Healthcare, in partnership with Johnson & Johnson (JNJ - Free Report) .
Glaxo is also working on expanding the label of marketed products like Nucala into additional indications
Conclusion
Glaxo faces its share of challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets.Meanwhile, its top-selling respiratory product, Advair is also expected to face generic competition in the United States this year, which will hurt sales.
However, it looks like Glaxo’s strong pipeline, consistent outperformance of new HIV drugs and vaccines, three new products, and cost cuts can bring it back on track this year.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>